Comp peptide and antibodies thereto for diagnosing osteoarthritis
AssigneeSGPTH Life Science AB
InventorsEva Skiöldebrand, Anders Lindahl, Stina Ekman
Life of this patent
Estimating the term…
Abstract
There is provided a peptide comprising the amino acid se-quence N-terminal-SGPTH and an antibody against this peptide. The peptide can be used for diagnosis in humans and animals, in particular horses. In particular the antibody can be used for diagnosis of a systemic low-grade chronic inflammatory disease such as osteoarthritis or atherosclerosis, or a neurodegenerative disease or neuroinflammatory disease.
Claims3
A method of diagnosing early osteoarthritis in a horse by an anti-NH2-SGPTH (SEQ ID NO:1) immunoassay comprising:
- contacting a serum or synovial fluid sample obtained from the horse with a rabbit polyclonal anti-NH2-SGPTH (SEQ ID NO:1) antibody;
- and
- detecting presence of NH2-SGPTH (SEQ ID NO:1) in the sample, wherein diagnosis of early osteoarthritis in the subject is characterized by increased detection of NH2-SGPTH (SEQ ID NO:1) compared to a control and a concentration of 30 μg/ml of NH2-SGPTH (SEQ ID NO:1) in the sample.
A method of diagnosing early osteoarthritis in a horse by an anti-NH2-SGPTH (SEQ ID NO:1) immunoassay comprising:
- contacting a serum or synovial fluid sample obtained from the horse with a anti-NH2-SGPTH (SEQ ID NO:1) antibody;
- and
- detecting presence of NH2-SGPTH (SEQ ID NO:1) in the sample, wherein diagnosis of early osteoarthritis in the subject is characterized by increased detection of NH2-SGPTH (SEQ ID NO:1) compared to a control and a concentration of 30 μg/ml of NH2-SGPTH (SEQ ID NO:1) in the sample.
A method of diagnosis of early osteoarthritis in a horse subject comprising:
- isolating a synovial fluid, blood, plasma, serum, or articular cartilage sample from the subject,
- providing an antibody means for specific binding to NH2-SGPTH SEQ ID NO:1;
- and
- analyzing the sample for presence or amount of NH2-SGPTH SEQ ID NO:1 in the sample by immunoassay, wherein diagnosis of early osteoarthritis in the subject is characterized by increased detection of NH2-SGPTH (SEQ ID NO:1) compared to a control and a concentration of 30 μg/ml of NH2-SGPTH (SEQ ID NO:1) in the sample.
Dependencies are inferred from the claim text.